December 1st, 2003 — Pittsburgh — TissueInformatics.Inc — "The World's Automated Pathology Software Company™".
TissueInformatics.Inc (www.TissueInformatics.com) announced today that Dr. Douglas R. Morton, Jr., Ph.D. has been appointed to the company's Board of Directors.
Dr. Morton most recently retired from Pfizer Inc. where he served as the company's vice president, worldwide discovery/strategic alliances and contributed to the integration of Pharmacia's drug discovery technology into Pfizer's research operations. Dr. Morton now holds the position of Chief Executive Officer of the Southwest Michigan Innovation Center (SMIC).
Over the past five years, Dr. Morton's role at Pharmacia, and subsequently Pfizer Inc., exposed him to the large global market for life science companies. This experience gives him a strong understanding of the needs of large pharmaceutical companies, and the capabilities of emerging biotech companies. Dr. Morton joins TissueInformatics with over 30 years of scientific and managerial experience including 25-years with The Upjohn Co. and Pharmacia-Upjohn.
"During my long scientific career, I have gained significant experience and expertise in drug discovery technology and development within large pharmaceutical companies. I am pleased to join the distinguished Board of Directors of TissueInformatics and I look forward to providing additional experience and guidance as TissueInformatics continues to successfully provide automated pathology software for their customers in the pharmaceutical and biotechnology industries." said Dr. Morton.
Dr. Morton graduated magna cum laude from Kenyon College, Ohio, with an A.B. in Chemistry. He was later awarded his Ph.D. in Organic Chemistry by Columbia University and went on to complete his postdoctoral studies in that field at Stanford University before joining Upjohn. Dr. Morton is the author or co-author of 45 peer-reviewed scientific publications and is the holder of 43 U.S. Patents.
Funded by notable investors such as the Aurora Funds, Birchmere Ventures, the Future Fund, InforMax, Manulife Financial, Motorola, Smithfield Trust and Techno Venture Management (TVM), TissueInformatics is The World's Automated Pathology SoftwareCompany™, accelerating the drug discovery process by providing a broad range of automated pathology software, tissue analysis services, and drug target discovery solutions to the pharmaceutical, biotechnology and CRO industries.
###
Statements in this press release that are not strictly historical are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks associated with TissueInformatics.Inc's (the "Company's") dependence upon the creation of strategic alliances with providers for complementary services and products and the need to keep pace with rapid technological change, the Company's dependence for future revenues on its ability to increase sales of its tissue imaging and analysis applications, the development and availability of competitive products or technologies, and the Company's dependence on patents and its ability to defend its intellectual property rights. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company's current outlook as of the date given.
Todd A. Joron
Senior Vice President
Sales & Marketing
(412) 327-4354
TJoron@TissueInformatics.com
Back to Portfolio News
